COAG Reports Q1 2026 Net Loss $22.7M, $23.98 EPS, $163.5M Cash
Hemab Therapeutics Holdings, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $28.50
+8.7% in 3d after detection
Post-detection moves
1h
—
1d
-1.6%
3d
+8.7%
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS